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Abstract
The purpose of this study was to assess the accuracy of parametric analysis of transvaginal 
contrast-enhanced ultrasound (TV-CEUS) for distinguishing benign versus malignant ovarian 
masses. A total of 48 ovarian masses (37 benign and 11 borderline/malignant) were examined with 
TV-CEUS (Definity, Lantheus, North Bilreca, MA; Philips iU22, Bothell, WA). Parametric 
images were created offline with a quantification software (Bracco Suisse SA, Geneva, 
Switzerland) with map color scales adjusted such that abnormal hemodynamics were represented 
by the color red and the presence of any red color could be used to differentiate benign and 
malignant tumors. Using these map color scales, low values of the perfusion parameter were 
coded in blue, and intermediate values of the perfusion parameter were coded in yellow. 
Additionally, for each individual color (red, blue, or yellow), a darker shade of that color indicated 
a higher intensity value. Our study found that the parametric mapping method was considerably 
more sensitive than standard ROI analysis for the detection of malignant tumors but was also less 
specific than standard ROI analysis. Parametric mapping allows for stricter cut-off criteria, as 
hemodynamics are visualized on a finer scale than ROI analyses, and as such, parametric maps are 
a useful addition to TV-CEUS analysis by allowing ROIs to be limited to areas of highest 
malignant potential.
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Introduction
It is estimated that 24,000 women in the United States will be diagnosed with ovarian cancer 
this year, leading to approximately 14,000 deaths nationwide due to the disease. Even more 
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staggering are the statistics for ovarian cancer worldwide—an estimated 204,449 patients 
will be diagnosed with the disease, and approximately 124,860 women across the globe will 
die of the disease.1 Unfortunately, out of all the gynecological cancers, ovarian cancer is 
associated with the highest mortality and remains a disease with a poor prognosis.2 
Additionally, while the incidence of ovarian cancer has been steadily increasing over the 
past 10 years with the overall lifetime risk of the disease now at 1.8%, survival rates for the 
disease have remained relatively stagnant over the past 40 years despite innovations in both 
surgical technique and chemotherapeutic drugs, neither of which have managed to impact 
the overall mortality rate.1,3 This is in part due to difficulties in early detection of the 
disease. While women diagnosed with stage I disease—disease which is confined to the 
ovary—often require less invasive or extensive treatments and carry a 5-year survival of 
approximately 90%, women with stage III or stage IV disease have a 5-year survival rate of 
only 27% and 16%, respectively.4 It is the hope that through earlier detection and more 
accurate diagnosis of early-stage cancers, the prognosis and overall disease-related mortality 
for this disease can be impacted in a positive manner.
A variety of imaging studies are used in the pre-operative evaluation of ovarian masses 
including: transabdominal or transvaginal sonography, computed tomography (CT), 
magnetic resonance imaging (MRI), and positron emission tomography (PET). However, 
many of these modalities are limited in their accurate assessment of adnexal masses. For 
example, while both CT and MRI can detect large pelvic masses, their ability to accurately 
characterize smaller ovarian masses is limited. As a result, many patients end up undergoing 
surgical procedures for both the diagnosis and as well as the possible treatment of benign 
and malignant ovarian disease.5
Ultrasonography is an established method for the evaluation of adnexal masses, and the 
advantages to using transvaginal sonography (TVS) include the ability to offer high-
resolution imaging combined with a modality that uses no ionizing radiation and that is 
widely available. Previously, the evaluation of ovarian masses using conventional TVS 
suffered from somewhat limited sensitivity and specificity with regards to the definitive 
diagnosis of ovarian cancer due to certain overlapping characteristics shared by both benign 
and malignant tumors.5 However, significant technological improvements in the 
sonographic imaging of ovarian cancer have resulted in advances in the detection of benign 
versus malignant disease, and a recent European multicenter study which established a set of 
“simple rules” for the distinction of benign and malignant ovarian masses yielded a 
sensitivity of 93% and a specificity of 90%.6 With the advent of three-dimensional 
transvaginal sonography, the ability to demonstrate the morphological characteristics of 
ovarian masses surpassed the capability of traditional TVS, and the use of color Doppler 
assists in the identification of neovascularity in malignant tumors.7 However, transvaginal 
color Doppler sonography (TV-CDS) is only able to demonstrate the network of 
macrovessels between 100 and 200 microns in diameter, and unfortunately, it has not aided 
in the diagnosis of malignant ovarian tumors in general populations.8–10 Although TV-CDS 
is unable to visualize the microvessel capillary network of tumors, the use of contrast-
enhanced transvaginal sonography (CE-TVS) using intravascular microbubble contrast 
permits the depiction of vessels less than 40 microns in diameter.11
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Traditionally, the CE-TVS time-intensity curve has been averaged over a region of interest 
(ROI) covering solid components of masses with the highest malignant potential (irregular 
solid area, papillary excresences, and septa). However, parametric mapping of the time-
intensity curve allows for the global visualization of tumor hemodynamics on a pixel-by-
pixel basis. While parametric imaging has been used to differentiate malignant focal liver 
and breast masses, it has not been widely applied to the evaluation of ovarian masses and 
has remained limited to selecting the pixel with the greatest peak enhancement (PE) and 
using that pixel’s time-intensity curve for analysis.11–13 The aim of this study was to assess 
the accuracy of parametric analysis of TV-CEUS for distinguishing benign versus malignant 
ovarian masses using histology as a reference standard.
Materials and Methods
48 patients ages 24–73 years (average +/− SD, 48.3 +/− 2.1 years) with morphologically 
abnormal ovarian masses smaller than 10 cm who had been referred for surgical treatment 
were examined with TV-CEUS. A morphologically abnormal mass was defined as: solid or 
cystic with papillary excrescences, focally thickened walls, or irregular solid areas. 
Retrospective analysis included data obtained from our previously reported published series 
as well as the data from 19 additional patients.14,15 All patients with known right-to-left, 
bidirectional, or transient right-to-left cardiac shunts as well as a hypersensitivity reaction to 
the contrast agent or its components were excluded from the study. After thorough 
evaluation and screening by gynecologic oncologists and radiologists, all patients were 
scheduled for surgical treatment. The study was approved by the Institutional Review Board, 
and written informed consent was obtained from each patient. All women in the study were 
treated by oophorectomy using surgical laparoscopy or laparotomy within 3 days of the 
sonographic examination. Final histologic diagnoses were obtained for all lesions included 
in the study and were used as reference standards.
As the first part of the examination, transvaginal gray scale sonography was performed with 
an iU22 scanner (Phillips Medical Systems, Bothell, WA) and an 8-5 convex transvaginal 
probe to identify the ovarian mass. An experienced sonographer performed all the scans, 
after which color Doppler sonography was used to identify the area of the tumor with the 
most prominent vascularity. Once this region of interest (ROI) was assigned based on the 
gray scale and color Doppler sonographic findings, a contrast-enhanced study of the area 
was conducted to optimize the visualization of the mass.
A 3 µL/kg dose of perflutren microbubble contrast agent (Definity; Lantheus, North 
Billerica, MA) was injected into an antecubital vein over 2 seconds. This was subsequently 
followed by a bolus of 10 mL of normal saline. Per the manufacturer’s recommendation for 
Definity, the patient’s blood pressure, respiration, heart rate, and oxygen saturation were 
monitored both during the procedure as well as for 15 to 20 minutes after the procedure. A 
3-minute cine loop recording was started at the time of the intravenous injection, and the 
sonographer was instructed not to move the transducer during the 3-minute recording. The 
acquired 3-minute cine loops were stored on the scanner’s internal hard drive and exported 
to a computer workstation for later analysis. Following this, the injection was repeated (up 
to 2 injections of the contrast agent per tumor examined). Both cine loops were analyzed, 
Korhonen et al. Page 3
Ultrasound Q. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and the recording that showed the most prominent enhancement for each tumor was chosen 
for further study and evaluation. Each 3-minute video clip was then analyzed offline.
Image analysis was performed offline using quantification software prototype (Bracco 
Suisse SA, Geneva, Switzerland). Using the intravenous contrast signals, the software 
creates color-coded parametric maps of each perfusion parameter on a pixel-by-pixel basis 
for the previously defined region of interest in each mass.
First, a conventional ROI average analysis was performed. A region of interest (ROI) for 
each mass was manually placed to include all solid components and papillary projections 
while excluding any cystic areas or septations. Multiple parameters that have been 
previously described as having some potential diagnostic accuracy in CEUS cancer 
diagnosis were evaluated. The following contrast kinetic parameters were examined: time to 
peak (Tp; the time from injection of the contrast agent to peak signal intensity, measured in 
seconds), peak enhancement (PE; peak signal intensity during the contrast transit, measured 
in dB), wash-in AUC (WiAUC; the integral of the contrast wash-in curve, measured in 
arbitrary units, a.u), wash-out AUC (WoAUC; the integral of the contrast wash-out curve, 
measured in a.u), wash-in-wash-out AUC (WiWoAUC; the integral of the contrast wash-in 
and wash-out curve, measured in a.u), and wash-out rate (WoR; rate of wash-out of the 
contrast agent, measured in a.u).
For each examined contrast kinetic parameter, the values within the ROI were averaged. 
Then, receiver operating characteristic (ROC) curves were created to determine cut-off 
criterion with best diagnostic accuracy for ovarian cancer. These values were based on 
receiver operator curves obtained from the authors’ original data optimizing sensitivity and 
specificity.15 These cut-offs were used as a threshold values to create parametric maps of the 
ovarian lesions. For all diagnostic criteria, the cut-off with maximal diagnostic accuracy was 
chosen based on the ROC analysis.
For each perfusion parameter, map color scales were adjusted such that abnormal 
hemodynamics were represented by the color red, and the presence of any red color was 
used to differentiate benign and malignant tumors. Using these map color scales, low values 
of the perfusion parameter were coded in blue, and intermediate values of the perfusion 
parameter were coded in yellow. Additionally, for each individual color (red, blue, or 
yellow), a darker shade of that color indicated a higher intensity value. These abnormal 
hemodynamics were represented on the map color scales by the color red for: PE > 24 a.u, 
Tp; < 11 seconds, wiAUC > 35 a.u, WoAUC > 38 a.u, WiWoAUC > 38 a.u, or WoR > 9 
a.u.. Cutoffs were chosen based on optimum points on receiver operating curves.
In order to compare parametric mapping to traditional TV-CEUS analysis, ROI analysis was 
also performed using the same perfusion parameters (PE, Tp;, wiAUC, WoAUC, 
WiWoAUC, and WoR) as were used in the parametric mapping. A region of interest (ROI) 
for each mass was identified and defined by the operator analyzing the time-intensity curves. 
The ROI was manually selected and drawn to include all solid components and papillary 
projections while excluding any cystic areas or septations. The ROI was kept constant in 
size between subjects, and the operator was unaware of the histologic diagnosis of each 
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mass prior to or while performing this analysis. ROI analysis was performed by averaging 
the parameters from all pixels of the time-intensity curve corresponding to the selected 
region of interest, and receiver operating characteristic (ROC) curves were created to 
determine cut-off criterion with best diagnostic accuracy.
Statistical analysis was performed with means and 95% confidence intervals (CIs). The test 
sensitivity was defined as a true positive rate of ovarian cancer diagnosis. The analysis of 
variance test was used to compare the contrast parameters of enhancing benign versus 
malignant ovarian masses. The results were considered significant at P < 0.05.
Results
A total of 48 masses were studied. Of these, 37 were benign while 11 masses were 
malignant. The histologic types of the ovarian masses are listed in Table 1.
The results of the parametric analysis are shown in Table 2, while representative images of 
parametric maps can be seen in Figures 1, 2, 3, 4, and 5. Our results show the greatest 
diagnostic sensitivity for maps of wash-out related variables such as WoAUC (sensitivity 
100%), WiWoAUC (sensitivity 100%), and WoR (sensitivity 90.9%); however, these 
parameters suffered from somewhat lower specificity, with specificity values ranging from 
48.6% (WoAUC and WiWoAUC) to 64.9% (WoR). Similarly, while both the PE and Tp 
were highly sensitive (100%), these parameters were the least specific on parametric maps, 
with the specificity of PE being 32.4% and that of Tp being 8.1%. The WiAUC remained a 
somewhat moderately sensitive (63.6%) and highly specific (89.2%) parameter during 
parametric analysis.
The results of the standard ROI analysis are shown in Table 3. The mean values for PE 
(p=0.0004), WiAUC (p=0.0070), WoAUC (p=0.0015), WiWoAUC (p=0.0031), and WoR 
(p=0.006) were all significantly different between benign and borderline/malignant tumors, 
while the mean values for Tp were not significant in benign versus borderline/malignant 
tumors.
A comparison of parametric analysis versus ROI analysis can be found in Table 4. While 
parametric analysis was consistently of equal (as for WiAUC) or higher sensitivity (as for 
PE, Tp, WoAUC, WiWoAUC, and WoR) than standard ROI analysis for all parameters 
analyzed, the specificity of parametric maps was reduced significantly when compared to 
specificity values for standard ROI analysis. Only the WiAUC parametric mapping achieved 
greater specificity than standard ROI analysis, and this was only by a margin of 0.1%.
Discussion
Contrast-enhanced TVS can significantly augment the diagnostic capacity of transvaginal 
sonography in identifying tumor neovascuarlization on a microvessel scale.11, 14, 16–17 This 
is a substantial improvement in the potential diagnostic ability of sonography when 
compared to previous technology such as color Doppler imaging, which is limited 
demonstrating macrovessels within malignant tumors.8 Given the poor prognosis of ovarian 
cancer when it is detected at a later stage, the identification of early microvascular changes 
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associated with early-stage ovarian cancer development is critical in reducing mortality 
associated with the disease, which has unfortunately remained relatively stagnant over the 
past 40 years.1
Several prior studies have demonstrated the use of contrast-enhanced TVS in the 
differentiation between benign and malignant ovarian tumors due to the greater peak 
enhancement and more prolonged contrast washout time in malignant tumors as compared 
to benign tumors.18 However, simple documentation of tumor enhancement is not 
necessarily sufficient because some benign tumors show detectable contrast enhancement. 
To address this limitation, a few studies using enhancement kinetic parameters of the 
contrast agent to compare benign versus malignant tumors in the power Doppler mode have 
been performed. Using color Doppler sonography, Orden et al (2003) demonstrated that 
malignant and benign adnexal masses behaved differently with regards to degree, onset, and 
duration of Doppler US enhancement after injection with microbubble contrast, and 
according to the study from Marret et al (2004), the wash-out times and AUC were 
significantly greater in malignant ovarian tumors than in other benign ovarian masses.16, 19
Our preliminary clinical studies evaluated enhancement parameters in benign and malignant 
adnexal masses using pulse inversion nonlinear imaging, a new method of CE-TVS which 
provides more consistent and reliable estimates of tumor vascularity and perfusion compared 
to traditional Doppler-based CE-TVS. Our data indicated that the peak enhancement and 
wash-out parameters had the best sensitivity and specificity for the diagnosis of malignant 
ovarian tumors while the wash-in and time to peak parameters were less accurately 
predictive of malignant status, possibly related to its variability with regards to contrast 
injection and circulation times.15 As such, during the next phase of our study, we analyzed 
the use of enhancement variables with parametric mapping, a technique which had 
previously been used in determination of focal liver and breast masses.12,13 To our 
knowledge, only the study by Testa et al (2009) has explored the use of parametric mapping 
in ovarian cancer detection. Although the study by Testa et al (2009) used parametric 
mapping, its application remained limited to selecting the pixel with the greatest peak 
enhancement and using that pixel’s time-intensity curve for analysis rather than using the 
map strictly for differentiation of benign versus malignant masses.11
Parametric mapping allows the finer scale visualization of tumor neovascularity on a pixel-
by-pixel basis, and ideally, in identifying early microvessel changes that might be associated 
with malignancy, parametric maps could be used to detect ovarian cancer in earlier stages, 
as late diagnosis of advanced disease carries a poor prognosis.4 While our study 
demonstrated that parametric maps were more sensitive than standard ROI analysis, they 
were considerably less specific than standard ROI analysis. Our methods were designed to 
give a high sensitivity, as is needed for any screening test, and therefore the specificity was 
somewhat reduced. We selected cut-off values with a high sensitivity (and therefore 
somewhat lower specificity) to detect lesions requiring further evaluation with other 
confirmatory tests such as MRI. Although a higher sensitivity is ideal for a screening test, as 
it is indicative of a test’s ability to identify true positive results, a good diagnostic test 
requires both high sensitivity as well as high specificity. Otherwise, it will fail to identify 
patients who are truly negative for the disease and risks exposing patients to both further 
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medical testing as well as potentially unnecessary procedures and interventions. Thus, 
despite its reduced sensitivity compared to parametric maps in our study, standard ROI 
analysis with its consistently higher specificity values is more accurate than parametric maps 
in differentiating benign from malignant ovarian masses. However, despite this, we do 
believe that parametric mapping serves a useful purpose when applied as part of screening 
measures rather than the sole diagnostic test.
Although parametric mapping might not provide the best diagnostic accuracy for ovarian 
cancer, its use has significant potential benefit in TV-CEUS. Parametric mapping allows for 
stricter cut-off criteria since hemodynamics are visualized on a finer scale than in ROI 
analyses based on mean time-intensity curves for heterogeneous regions chosen on 
morphology alone. Because potentially small areas of neovascularity can be overlooked in 
standard ROI analysis as these pockets are averaged over larger areas, parametric mapping 
are a useful addition to TV-CEUS analysis by allowing ROIs to be limited to areas of 
highest malignant potential.
There are several limitations of this study. Since this is a pilot study, no inter- and intra-
observer ROI selection variability analysis was performed. Another potential limitation of 
our study includes the sample size of masses evaluated. Although we analyzed 48 adnexal 
masses, only 11 of these were borderline or malignant ovarian tumors while 37 of these 
were benign masses. Additionally, although parametric mapping detects small areas of 
neovascularity that might not be detected with traditional ROI analysis, it is possible that 
certain benign or inflammatory processes might also demonstrate changes in vascularity 
detected by parametric mapping, and this might contribute towards the somewhat reduced 
specificity in our study. Similarly, it is possible that different histological subtypes of 
borderline or malignant ovarian tumors might demonstrate vastly different enhancement 
patterns and that certain subtypes might be more amenable to accurate diagnosis with 
parametric mapping. Even though our study analyzed a wide range of different subgroups of 
borderline/malignant tumors, some of these subtypes only contained a sample size of n=1 or 
n=2. As a result, future larger-scale studies with more borderline or malignant tumors 
evaluated would be helpful in further evaluation of the use of parametric mapping analysis. 
Additionally, in this study, only qualitative analysis of the parametric naps was performed, 
and only one criterion cut-off was analyzed for each parameter. More advanced quantitative 
methods of parametric map analysis, including testing multiple other cut-off values, should 
be performed to improve diagnostic accuracy of this method and improve test sensitivity and 
specificity.
In summary, parametric mapping remains an area of significant potential benefit in the 
diagnosis of ovarian cancer, with particular emphasis on the earlier diagnosis of this dreaded 
disease. The advantages of parametric analysis include the ability to visualize abnormal 
tumor hemodynamics on a pixel-by-pixel level with the added of benefit of potentially 
demonstrating small areas of neovascularization indicative of early malignant changes that 
might be missed using standard ROI analyisis. While our results demonstrated that 
parametric mapping can be a highly sensitive method for determining if an ovarian mass is 
benign versus malignant, parametric maps alone were considerably less specific than 
standard ROI analysis in making this distinction. We found the enhancement parameters of 
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wash-out AUC, wash-in-wash-out AUC, and wash-out rate to be the most diagnostically 
accurate out of all the parameters included in our study, and the peak enhancement and time 
to peak variables were less helpful. Overall, parametric maps are a useful addition to 
traditional TV-CEUS analysis by allowing for ROIs to be limited strictly to the areas of the 
most malignant potential, and, as such, parametric mapping remains a significant area of 
potential exploration and development in the field of ovarian cancer diagnosis.
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Figure 1. 
Parametric map of a corpus luteum cyst during peak enhancement (a), time to peak (b), 
wiAUC (c), woAUC (d), wiwoAUC (e), and woR (f). Map color scales were constructed to 
show possible tumor neovascularity as shades of red. The majority of the region of interest 
is depicted in blue colors with the exception of time to peak, which was shown to be non-
specific.
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Figure 2. 
Parametric map of a fibrothecoma during peak enhancement (a), time to peak (b), wiAUC 
(c), woAUC (d), wiwoAUC (e), and woR (f). Consistent with the rest of our analysis, the 
time to peak was the least specific for detecting malignancy out of all the variables analyzed, 
as dark red areas are supposed to correlate with abnormal hemodynamics.
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Figure 3. 
Parametric map of a serous borderline tumor during peak enhancement (a), time to peak (b), 
wiAUC (c), woAUC (d), wiwoAUC (e), and woR (f). All six enhancement kinetic 
parameters studied revealed marked areas of dark red indicating malignancy, and this was 
later correlated with histopathology.
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Figure 4. 
Parametric map of a serous adenocarcinoma during peak enhancement (a), time to peak (b), 
wiAUC (c), woAUC (d), wiwoAUC (e), and woR (f). Areas of tumor neovascularity in red 
contrast sharply with the cystic portion of the tumor shown in blue.
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Figure 5. 
Parametric map of metastatic breast cancer during peak enhancement (a), time to peak (b), 
wiAUC (c), woAUC (d), wiwoAUC (e), and woR (f). Multiple areas of tumor 
neovascularity, as shown as shades of red, are present.
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Figure 6. 
a direct, side-by-side comparison of parametric maps of the above benign fibrothecoma 
(from Figure 2) and above borderline serous adenocarcinoma (from Figure 3).
Korhonen et al. Page 15
Ultrasound Q. Author manuscript; available in PMC 2016 June 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Korhonen et al. Page 16
Table 1
Histologic types of ovarian masses
Type N=
Benign (n=37)
  Simple cyst 10
  Endometrioma 6
  Serous cystadenoma 7
  Corpus luteum cyst 5
  Teratoma 3
  Mucinous cystadenoma 3
  Fibroma 2
  Paraovarian/paratubal cyst 1
Malignant (n=11)
  Serous adenocarcinoma 5
  Endometriod adenocarcinoma 2
  Borderline serous adenocarcinoma 2
  Borderline mucinous cystadenocarcinoma 1
  Breast cancer metastasis 1
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